The Pharmaceutical Benefits Advisory Committee (PBAC) has agreed there is a need for interferon-free treatment regimens for people with hepatitis C – genotypes 4 and 6. At its July meeting PBAC recommended that the combination of grazoprevir + elbasvir (Zepatier®) be listed on the Pharmaceutical Benefits Scheme (PBS). It was also recommended as a further option for people with genotype 1. Merck Sharpe and Dohme, who produce the medicine, also sought PBS listing for genotype 3 but PBAC considered there was insufficient data to support use with genotype 3 at this time.
Once approved by the Health Minister this new medicine will join the other antiviral medicines for hepatitis C that started becoming available in March this year. Once formally approved Hepatitis Australia will update the current treatment factsheets for circulation.
To find out more about currently available treatments for hepatitis C click on the link below.